Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.
CGD Policy Blogs
The World Bank’s International Development Association (IDA), the largest single source of concessional financing for development in lower-income countries, is under-utilized in the world’s fight against pandemics, and can deploy its resources and expertise to play a much more significant role in the COVID-19 response and beyond as part of its upcoming replenishment, known as IDA20.
Make Me a Match: We Want Your Ideas to Kick-Start Promising Global Health Innovations with Demand-Side Funding
Scientific and technological innovation has the potential to save lives, reduce global poverty, and help address the most pressing global challenges—but investments in R&D are mostly directed at lucrative, high-income markets versus the health problems that affect the global poor.
In this blog, we explore three key actions linked to strategic purchasing that India’s AB-PMJAY scheme can apply by leveraging its influence as a major purchaser of services and goods in the country. These same actions are readily generalizable and can replicated by other jurisdictions to save money, improve health and accelerate a country’s journey towards UHC.
In January 2021, India embarked on one of the world’s largest vaccination drives ever in an attempt to control COVID-19 in the country. After nine months, 29 percent of the national population is partially vaccinated, and only 15 percent is fully vaccinated.
Next week, Atul Gawande, the prominent author, surgeon, researcher, and—most recently—presidential nominee to lead USAID’s Bureau for Global Health, will appear before the Senate Foreign Relations Committee for his nomination hearing to serve as Assistant Administrator.
Before Recommending the RTS,S Malaria Vaccine for Wider Use, WHO Should Address Three Key Considerations
Last month, the world woke up to promising news on malaria prevention: administering an existing malaria vaccine (RTS,S) in addition to antimalarial drugs before the rainy season reduced child hospitalizations and deaths by approximately 70 percent in Burkina Faso and Mali. These results arrived ahead of a forthcoming decision from the World Health Organization on whether to recommend RTS,S for broader use. This blog argues that WHO should consider value for money and address three key considerations before making their reccomendation.
Germany has stepped up as an important player in global health in recent years, rising to become the third largest government donor to health in 2019. Notably, Germany has played a key role in WHO reform efforts; it is the largest donor to WHO for the 2020-21 budget period, and one of the largest WHO emergency fund donors. Germany has also played a leading role politically, placing health on the agenda of the G-20 for the first time in 2017 and trying to tackle increasing global health fragmentation as co-initiator of the Global Action Plan.
Last month, CGD hosted an event on predicting the frequency and scale of future pandemics to discuss what’s to come after the COVID-19 pandemic and the critical task of preparing for future outbreak probabilities. This blog highlights three key takeaways from the event.
UNICEF’s Executive Director, Henrietta Fore, recently announced that she will step down from her position. With a change in leadership imminent, we consider the organization’s dual imperative: to protect children during humanitarian crises - including the current COVID-19 crisis-, and to shift from direct service delivery towards support for systems and policies that will drive sustainable improvements in child well-being today and tomorrow.